Brasofensine

Brasofensine (NS-2214, BMS-204756) is a phenyltropane that had been under development by Bristol-Myers Squibb for the treatment of Parkinson's and Alzheimer's diseases. In animal models of Parkinson's disease, brasofensine was effective in stimulating LMA[expand acronym] and reversing akinesia.[1] Phase II trials in humans were conducted in 1996 and brasofensine was shown to be both effective and well tolerated at a dose of 4mg;[2] however, dev... [wikipedia]